Bioanalysis Strategies of AAV Gene Therapy Drugs
The 2022 Chinese Pharmaceutical Association Pharmaceutical Bioanalysis Society (hereinafter referred to as CBF) was officially held on June 17. The venue was divided into a main venue and three sub-venues: DMPK sub-venue, bioanalysis sub-venue and biomarker sub-venue. From 13:30 to 14:00 on June 19, Dr. Li Zhiyan, Director of Bioanalysis of Xihua Biopharmaceuticals, will give a keynote report on "Bioanalysis Strategies of AAV Gene Therapy Drugs" at the bioanalysis venue.
Release time : 2022-06-19